Warwick BD Allan Department of Anaesthesia and Critical
Care, Royal Berkshire Hospital wbdallan@doctors.org.uk perhaps it would have been prudent for us to make this clearer in our original article. However, this solution was based on the very same principles and challenges on which the original pathway was based, and on which our article focuses; we believe the latter to be more informative and appropriate than simply offering our own alternative guidance.
To paraphrase statements from our original article: "Whatever happens, we must not allow patients to die in pain and discomfort... We also cannot abandon end-of-life care as too hard; we owe it to our patients and their relatives to put in place a system which starts with discussion and decisionmaking before moving to a recognised means of implementing that (palliative) care." We believe that these (and other) comments are very much of the same sentiment as those of Drs Correspondence regarding: Atrial fibrillation in the intensive care setting W e read with interest the review article "Atrial fibrillation in the intensive care setting" by Malik and colleagues, in the April 2013 edition of JICS. New onset atrial fibrillation (AF) is indeed the most common arrhythmia in the critically ill. 1 In the "Management of AF" section of the paper the authors did not acknowledge the role of intravenous (IV) magnesium in restoration of sinus rhythm (SR) and rate control of acute onset AF in the haemodynamically stable intensive care unit (ICU) patient. Magnesium is a calcium and potassium channel antagonist and electrophysiological studies have demonstrated slowed cardiac conduction and increased cardiac refractoriness with administration of IV magnesium. This suggests that it may inhibit re-entrant circuits within the atria responsible for development of AF. 2 Moran et al showed that parenteral magnesium is superior to amiodarone in the conversion of new onset AF in general ICU patients and may be equally as effective as amiodarone in rate control. 3 It has also been demonstrated that aside from rhythm and rate control magnesium sulphate acts synergistically with other antiarrhythmic drugs (eg digoxin) 4 and prevents proarrhythmic activity. It is cost effective and has a favourable tolerability profile. 5 The combination of magnesium sulphate and betablocker is not recommended. 6 The recommended antiarrhythmic IV dose of magnesium sulphate is 8 mmol (2g) over 10-15 minutes (repeated once if necessary). 7 Different regimens have been used in clinical trials including a bolus of
